MLN4924: Advancing NEDD8-Activating Enzyme Inhibition in Cancer Research

Introduction

The post-translational modification of proteins by ubiquitin-like molecules is a fundamental regulatory mechanism in eukaryotic biology. Among these, neddylation—the covalent attachment of NEDD8 to substrate proteins—plays a pivotal role in controlling the stability, activity, and localization of numerous cellular proteins. Aberrant neddylation has been implicated in tumorigenesis, particularly through dysregulation of the cullin-RING ligase (CRL) ubiquitination machinery. As the only known NEDD8-activating enzyme (NAE) inhibitor to have advanced to clinical evaluation, MLN4924 (pevonedistat) provides a unique tool for cancer biology research, enabling precise dissection of the neddylation pathway and the development of novel anti-cancer therapeutic strategies.

The Neddylation Pathway and Its Role in Cancer

Neddylation is a multi-step enzymatic process catalyzed by E1 (NAE), E2 (NEDD8-conjugating enzymes, e.g., UBE2M and UBE2F), and E3 (NEDD8 ligases) enzymes. In mammals, neddylation predominantly activates CRLs, the largest family of E3 ubiquitin ligases, which target a wide array of cell cycle and survival regulators for proteasome-mediated degradation. Dysregulation of this pathway is associated with numerous cancers and has been shown to promote tumor cell proliferation, genomic instability, and resistance to apoptosis.

Recent studies have expanded the significance of neddylation beyond cullins to include non-cullin substrates. Notably, RHEB—a small GTPase and master activator of mTORC1—has been identified as a direct substrate of the UBE2F-SAG neddylation axis, modulating mTORC1 activity and aggravating liver tumorigenesis (Zhang et al., 2025). These findings underscore the therapeutic potential of targeting neddylation at the level of NAE, the apex of the pathway, to disrupt downstream oncogenic signaling.

MLN4924: Mechanism of Action and Selectivity

MLN4924 is a potent, selective inhibitor of NAE, exhibiting an in vitro IC₅₀ of 4 nM. MLN4924 acts as an adenosine sulfamate analog that covalently binds to the active site of NAE, competing with ATP and thereby blocking the activation and transfer of NEDD8 to E2 enzymes. This inhibition prevents the formation of Ubc12–NEDD8 thioester intermediates as well as conjugation of NEDD8 to cullins and other substrates.

Importantly, MLN4924 displays high selectivity for NAE over other E1 enzymes, including the ubiquitin-activating enzyme (UAE), SUMO-activating enzyme (SAE), UBA6, and ATG7, as demonstrated by significantly higher IC₅₀ values for these off-targets. This selectivity is crucial for minimizing confounding effects on ubiquitin and SUMO signaling, allowing the specific interrogation of the neddylation pathway in cancer models.

MLN4924 in Cancer Biology Research

MLN4924 has emerged as a cornerstone compound for investigating the roles of neddylation in cancer cell proliferation, cell cycle regulation, and tumorigenesis. In cellular models, such as HCT-116 human colon carcinoma cells, MLN4924 induces dose-dependent inhibition of NAE activity, resulting in accumulation of CRL substrates. Among these, CDT1—a DNA replication licensing factor—accumulates upon neddylation inhibition, leading to DNA re-replication, S-phase arrest, and apoptosis.

Preclinical studies have demonstrated that MLN4924 impairs the degradation of a wide array of CRL-regulated proteins, including p27^Kip1, p21^Cip1, and IκBα, thereby modulating cell cycle checkpoints, DNA damage response, and NF-κB signaling. The specificity of MLN4924 enables the systematic dissection of CRL-dependent proteostasis and its impact on cancer cell fate.

Translational Applications: Tumor Growth Inhibition in Solid Tumor Models

The anti-tumor efficacy of MLN4924 has been validated in multiple xenograft models. In vivo, subcutaneous administration of MLN4924 at 30 mg/kg and 60 mg/kg leads to significant tumor growth inhibition in solid tumor models, including HCT-116 colon cancer, H522 lung tumor, and Calu-6 lung carcinoma xenografts, with minimal systemic toxicity and negligible weight loss. These findings underscore the translational relevance of NAE inhibitors for solid tumor studies and support their continued investigation in anti-cancer therapeutic development.

MLN4924’s robust pharmacological profile (molecular weight 443.53, high solubility in DMSO and ethanol, and stability at -20°C) further facilitates its adoption in both in vitro and in vivo research workflows, providing a reliable tool for mechanism-of-action and proof-of-concept studies.

MLN4924 and the Neddylation-mTORC1 Axis: New Insights from Recent Research

While cullin neddylation and CRL activity have long been considered the primary effectors downstream of NAE, emerging data highlight the broader impact of neddylation on non-cullin substrates and key oncogenic pathways. A recent study by Zhang et al. (2025) provides compelling evidence that RHEB, a critical mTORC1 activator, undergoes neddylation at lysine 169 by the UBE2F-SAG axis. This modification enhances RHEB lysosomal localization and GTP-binding affinity, driving mTORC1 hyperactivation and liver tumorigenesis.

Genetic depletion of UBE2F in cell and mouse models inactivates mTORC1, inhibits cell cycle progression, and suppresses hepatocellular carcinoma development, illuminating the therapeutic promise of neddylation blockade. Notably, the study correlates UBE2F expression and mTORC1 activity with poor patient outcomes in hepatocellular carcinoma, positioning the neddylation machinery as a clinically relevant target in solid tumors.

Given that MLN4924 targets NAE upstream of both cullin and non-cullin neddylation events, it provides an unparalleled means to interrogate the full spectrum of neddylation-dependent oncogenic processes, including the emerging RHEB-mTORC1 axis. Future research leveraging MLN4924 is poised to further elucidate the interplay between neddylation, mTORC1 signaling, and tumor cell metabolism.

Practical Considerations for MLN4924 Use in Research

For experimental reproducibility and optimal activity, MLN4924 should be handled according to established protocols. The compound is a solid with a molecular weight of 443.53, exhibiting solubility of at least 22.18 mg/mL in DMSO and 42.2 mg/mL in ethanol, but is insoluble in water. Stock solutions should be prepared fresh or stored at -20°C for short-term use to preserve activity and minimize degradation. These properties enable its application in diverse assay formats, ranging from high-throughput screening to mechanistic cell and animal studies.

When designing experiments, it is critical to utilize appropriate negative controls, such as vehicle-treated cells or animals, to account for potential off-target effects. Dose-response studies are recommended to establish the minimal effective concentration for NAE inhibition in the chosen model system. For in vivo studies, careful monitoring of animal health and weight is necessary to ensure tolerability, as established in prior xenograft work.

Future Perspectives: Neddylation Pathway Inhibition in Anti-Cancer Therapeutic Development

The advent of selective NAE inhibitors for cancer research, exemplified by MLN4924, has transformed our understanding of ubiquitin-like protein modifications in tumor biology. Ongoing investigations are expanding the repertoire of neddylation substrates and elucidating the context-dependent consequences of pathway inhibition in different cancer types.

The intersection of neddylation with mTORC1 signaling, as revealed by recent findings (Zhang et al., 2025), provides a mechanistic framework for targeting metabolic vulnerabilities in hepatocellular carcinoma and potentially other solid tumors. Further studies are warranted to dissect the downstream effectors of NAE inhibition, identify biomarkers of response, and optimize combination strategies with existing chemotherapeutics or targeted agents.

Conclusion

MLN4924 stands at the forefront of neddylation pathway inhibition, offering a highly selective, mechanistically validated approach to interrogate the role of NAE in cancer progression. By blocking cullin-RING ligase (CRL) ubiquitination and disrupting both canonical and emerging neddylation-driven oncogenic circuits, MLN4924 has illuminated new avenues for basic and translational cancer biology research. The recent demonstration of RHEB neddylation's impact on mTORC1 activity and liver tumorigenesis further accentuates the breadth of processes governed by NAE and the utility of MLN4924 as a research tool. As our understanding of the neddylation landscape deepens, MLN4924 and related agents will remain essential in the quest to translate mechanistic insights into effective anti-cancer therapies.

Contrast with Existing Literature

While previous reviews and studies have explored the general functions of neddylation and its role in CRL-mediated proteostasis, this article uniquely synthesizes recent mechanistic insights from Zhang et al. (2025) regarding the UBE2F-SAG-RHEB-mTORC1 axis, and places them in the context of experimental and translational use of MLN4924. By focusing on the intersection of neddylation pathway inhibition, mTORC1 signaling, and solid tumor models, this piece provides distinct, practical guidance for researchers aiming to exploit NAE inhibitors in novel anti-cancer therapeutic development. This approach differentiates it from existing publications, which have not yet integrated these emerging data or provided detailed protocols for the use of selective NAE inhibitors in cancer biology research.